Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model

Rinaldi, Monica; Fioretti, Daniela Piergili; Iurescia, Sandra; Signori, Emanuela; Pierimarchi, Pasquale; Seripa, Davide; Tonon, Giancarlo; Fazio, Vito Michele

doi:10.1016/j.bbrc.2008.03.076

Cited by 21 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We reported that DNA-based vaccination with a plasmid coding for the CDR3 region of an IgM m-chain as a target Ag was able to induce an Ab response specific for the CDR3 of the m-chain in two of three of vaccinated mice (49). We therefore inserted a sequence encoding for one CDR3-b belonging the BV10 public rearrangement (namely Y L C A S S P G T N T E V F F G [28]) in the expression box of the published plasmid vector pRC110-NTS-IL-2 with IL-2 encoded in a separate expression box (34). The resulting plasmid vector was named pRC110-NTS-IL-2-BV10.…”

Section: A S S P T N S Y N S P L Y F a A C A S S P T N S Y N S P L mentioning

confidence: 99%

See 1 more Smart Citation

Mycobacterium smegmatisExpressing a Chimeric Protein MPT64-Proteolipid Protein (PLP) 139–151 Reorganizes the PLP-Specific T Cell Repertoire Favoring a CD8-Mediated Response and Induces a Relapsing Experimental Autoimmune Encephalomyelitis

Nicolò¹,

Sali

Sante³

et al. 2009

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

We infected SJL mice with a recombinant Mycobacterium smegmatis expressing a chimeric protein containing the self-epitope of proteolipid protein 139–151 (p139) fused to MPT64, a secreted protein of Mycobacterium tuberculosis (rMSp139). Infected mice developed a relapsing experimental autoimmune encephalomyelitis (EAE), showing a prevailing demyelination of the CNS, and disease severity was significantly lower in comparison with the one that follows immunization with p139. rMSp139 was not detected in lymph node or spleen in the course of clinical disease development or in the CNS during relapse. Infection with rMSp139 modified the p139-specific T cell repertoire, recruiting the spontaneous p139-specific repertoire and activating CD4+ T cells carrying the BV4 semiprivate rearrangement. T cells carrying the public BV10 rearrangement that are consistently found in the CNS during flares of disease were not activated by infection with rMSp139 because lymph node APCs infected with rMSp139 selectively fail to present the epitope for which BV10 cells are specific. Simultaneously, rMSp139 expanded p139-specific CD8+ cells more efficiently than immunization with peptide in adjuvant. SJL mice vaccinated against the CDR3 sequence of the BV10 public rearrangement reduced usage of the BV10 cells and displayed reduced symptoms during bouts of EAE. Thus, transient peripheral infection with a CNS-cross–reactive nonpathogenic Mycobacterium induces a relapsing EAE that continues long after clearance of the infectious agent. The composition of the self-reactive repertoire activated determines severity and histology of the resulting disease.

show abstract

Section: A S S P T N S Y N S P L Y F a A C A S S P T N S Y N S P L mentioning

confidence: 99%

“…The DNA vaccine specific for the BV10 + p139-specific public TCR rearrangement was constructed in plasmid pRC110-NTS-IL-2 that was described previously (34). The nuclear targeting sequence (NTS) was used to facilitate nuclear plasmid uptake in murine skeletal muscle following naked DNA electroporation.…”

Section: Cdr3 Sequencingmentioning

confidence: 99%

Mycobacterium smegmatisExpressing a Chimeric Protein MPT64-Proteolipid Protein (PLP) 139–151 Reorganizes the PLP-Specific T Cell Repertoire Favoring a CD8-Mediated Response and Induces a Relapsing Experimental Autoimmune Encephalomyelitis

Nicolò¹,

Sali

Sante³

et al. 2009

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…VhCDR3 is overexpressed in Murine B cell lymphoma. Tumor free survival is 60% in Murine B cell lymphoma when immunization is used with VhCDR3 epitope-based DNA (Rinaldi et al, 2008). For patients immunized with CDR3-based fusion vaccine, tumor free survival is 50% (Iurescia et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Cancer Preventive Effects of Whole Cell Type Immunization against Mice Ehrlich Tumors

Ayşan

Bayrak²,

Aydemir³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Effects of whole cell type immunization on mice Ehrlich tumours were evaluated. Materials and Methods: After preliminary study, mice were divided two major groups; 1x1000 and 100x1000 live Ehrlich cell transferred major groups, each divided into four subgroups (n: 10). Study groups were immunized with Ehrlich cell lysates in 0, 3, 7, 14 th days and after 30 days of last immunization, live Ehrlich cells were transferred. Mice were observed for six months and evaluated for total and cancer free days. Results: Out of 100x1000 cell transferred solid type study group, all study group mean and tumour free periods were statistically longer than control groups. All 1x1000 Ehrlich cell transferred study groups survived significantly longer than 100x1000 Ehrlich cell transferred groups. Conclusions: Ehrlich mice tumours were prevented and survival prolonged with whole cell type immunization. Effects are related to the number of transferred tumor cells.

show abstract

“…imply the availability of both the tumour and the syngenic animal model in order to determine whether the epitopebased cancer vaccine is able to induce anti-tumour immunity and increase animal survival after tumour challenge [58].…”

Section: Web-based Tools For Epitope Predictionmentioning

confidence: 99%

Recent Advances in Epitope Design for Immunotherapy of Cancer

Chiarella

Massi²,

Robertis³

et al. 2009

PRA

Self Cite

View full text Add to dashboard Cite

Eradication of cancer cells is imperative for a successful treatment of tumours. In addition to the existent chemotherapy or radiation therapy, other novel immunotherapeutic strategies to fight tumours are currently under investigation. One of these is cancer vaccination, an approach aimed at inducing effective immune responses in the host against defined tumour antigens. Among several classes of cancer vaccines, the subunit vaccines based on the single and multi epitope-approach are worthy of note as they offer an exquisite specificity in targeting only tumour cells. In this review we will focus on the significant advances made in the development and use of epitope-based cancer vaccines, reporting a selection of important and recent patents on tumour antigen discovery and epitope design for immunotherapy of cancer.

show abstract

Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model

Cited by 21 publications

References 29 publications

Mycobacterium smegmatisExpressing a Chimeric Protein MPT64-Proteolipid Protein (PLP) 139–151 Reorganizes the PLP-Specific T Cell Repertoire Favoring a CD8-Mediated Response and Induces a Relapsing Experimental Autoimmune Encephalomyelitis

Mycobacterium smegmatisExpressing a Chimeric Protein MPT64-Proteolipid Protein (PLP) 139–151 Reorganizes the PLP-Specific T Cell Repertoire Favoring a CD8-Mediated Response and Induces a Relapsing Experimental Autoimmune Encephalomyelitis

Cancer Preventive Effects of Whole Cell Type Immunization against Mice Ehrlich Tumors

Recent Advances in Epitope Design for Immunotherapy of Cancer

Contact Info

Product

Resources

About